- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Acromegaly Functional Carcinoid Tumour Non-functional gastroenteropancreatic neuroendocrine tumour (GEP-NET)
- Meeting Date: July 2024
- Public Summary Document (PSD) July 2024 PBAC Meeting - (PDF 573KB)
- Public Summary Document (PSD) July 2024 PBAC Meeting - (Word 134KB)
Lanreotide – July 2024
Lanreotide; Injection 60 mg (as acetate) in single dose pre-filled syringe, Injection 90 mg (as acetate) in single dose pre-filled syringe, Injection 120 mg (as acetate) in single dose pre-filled syringe; Somatuline® Autogel
Last updated
30 May 2025